Literature DB >> 22205549

Chemotherapy line-associated differences in quality of life in patients with advanced cancer.

B Mayrbäurl1, L M Wintner, J M Giesinger, Th Himmelfreundpointner, S Burgstaller, B Holzner, J Thaler.   

Abstract

PURPOSE: The aim of this study was to investigate quality of life (QOL) differences between patients receiving first, second, or third-line palliative chemotherapy (CT).Furthermore, QOL was also compared to a sex- and age-matched sample of healthy controls.
METHODS: Patients with different metastatic cancers receiving palliative CT were approached to complete the EORTC QLQ-C30 questionnaire by means of touch-screen computers before the start of CT, after 3 cycles and at the end of cytostatic treatment.
RESULTS: One hundred four patients were recruited for QOL assessment (56.9% of patients in first, 22.5% second and 20.6% third- or above-line palliative CT). Compared to healthy controls, they suffered from substantial QOL impairments in all EORTC QLQ-C30 sub-domains. In regard to CT lines, patients with first-line CT reached better scores in emotional and social functioning than second-line patients and less financial difficulties than third-line patients. Despite the high level of impairment in the patient sample, electronic data collection proved to be feasible and well accepted.
CONCLUSIONS: The results indicate that patients receiving third- or above-line palliative CT are confronted with stronger QOL impairments than first- and second-line patients. Supported by its feasibility and acceptance of by patients, electronic QOL data capture is an attractive method to screen for symptoms and track their course within clinical routine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205549     DOI: 10.1007/s00520-011-1355-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  26 in total

1.  Response shift: a brief overview and proposed research priorities.

Authors:  Ruth Barclay-Goddard; Joshua D Epstein; Nancy E Mayo
Journal:  Qual Life Res       Date:  2009-02-25       Impact factor: 4.147

2.  Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.

Authors:  C Doyle; M Crump; M Pintilie; A M Oza
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients.

Authors:  P Taenzer; B D Bultz; L E Carlson; M Speca; T DeGagne; K Olson; R Doll; Z Rosberger
Journal:  Psychooncology       Date:  2000 May-Jun       Impact factor: 3.894

4.  Computerized quality-of-life screening in an oncology clinic.

Authors:  P A Taenzer; M Speca; M J Atkinson; B D Bultz; S Page; P Harasym; J L Davis
Journal:  Cancer Pract       Date:  1997 May-Jun

5.  Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.

Authors:  Florence Joly; Nadine Houédé; Sabine Noal; Christine Chevreau; Frank Priou; Paule Chinet-Charrot; Frédéric Rolland; Aude Fléchon; Michel Henry-Amar; Stéphane Culine
Journal:  Clin Genitourin Cancer       Date:  2009-08       Impact factor: 2.872

6.  Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel.

Authors:  Orlando Guntinas-Lichius; Sarah Rühlow; Florian Veelken; Jens Peter Klussmann
Journal:  J Cancer Res Clin Oncol       Date:  2008-12-16       Impact factor: 4.553

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Computerized symptom and quality-of-life assessment for patients with cancer part II: acceptability and usability.

Authors:  Kristin H Mullen; Donna L Berry; Brenda K Zierler
Journal:  Oncol Nurs Forum       Date:  2004-09-17       Impact factor: 2.172

9.  Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial.

Authors:  Galina Velikova; Laura Booth; Adam B Smith; Paul M Brown; Pamela Lynch; Julia M Brown; Peter J Selby
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

10.  Are gender-associated differences in quality of life in colorectal cancer patients disease-specific?

Authors:  Johannes Giesinger; Georg Kemmler; Verena Mueller; August Zabernigg; Beate Mayrbaeurl; Josef Thaler; Dietmar Ofner; Christian Pegger; Gerhard Rumpold; Barbara Weber; Barbara Sperner-Unterweger; Bernhard Holzner
Journal:  Qual Life Res       Date:  2009-04-01       Impact factor: 4.147

View more
  4 in total

1.  Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada.

Authors:  T E Delea; J Amdahl; H R Nakhaipour; S C Manson; A Wang; N Fedor; A Chit
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

2.  Quality of life of patients with advanced cancer treated in a regional hospital in Greece.

Authors:  T Konstantinidis; M Linardakis; G Samonis; A Philalithis
Journal:  Hippokratia       Date:  2016 Apr-Jun       Impact factor: 0.471

3.  Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.

Authors:  Jordan Amdahl; Stephanie C Manson; Robert Isbell; Ayman Chit; Jose Diaz; Lily Lewis; Thomas E Delea
Journal:  Sarcoma       Date:  2014-06-12

4.  Chemotherapy use and quality of life in cancer patients at the end of life: an integrative review.

Authors:  Elham Akhlaghi; Rebecca H Lehto; Mohsen Torabikhah; Hamid Sharif Nia; Ahmad Taheri; Ehsan Zaboli; Ameneh Yaghoobzadeh
Journal:  Health Qual Life Outcomes       Date:  2020-10-07       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.